CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

RenovoRx, Inc.

RNXT
$77MMicro Cap

Next catalyst

Phase 3January 2027

Phase 3

Get an email about RNXT's next catalysts

Track RenovoRx (RNXT) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

No other upcoming event in our data.

Catalyst Timeline

1 upcoming, 1 past

Phase 3Next

Phase 3

January 2027~

RenovoRx announced its TIGeR-PaC Phase III trial has enrolled over 100 patients with enrollment expected to complete in H1 2026 and final data anticipated in 2027.

Source

How RNXT's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQSurgical & Medical Instruments & ApparatusPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaMOUNTAIN VIEW

Frequently asked questions

What is in RenovoRx, Inc.'s drug pipeline?β†’

CatalystAlert tracks 11 drug candidates in RenovoRx, Inc.'s (RNXT) pipeline across Phase 3, Phase 2. Its lead program is estradiol (Zesteem) (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is RenovoRx, Inc.'s next FDA catalyst?β†’

RenovoRx, Inc.'s (RNXT) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track RNXT biotech catalysts?β†’

Add RNXT to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow RenovoRx, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply